Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Mitoxantrone (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Sep 2018.
- 08 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2017.